BCL-W makes only minor contributions to MYC-driven lymphoma development

The BH3-mimetic drug Venetoclax, a specific inhibitor of anti-apoptotic BCL-2, has had clinical success for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia. Attention has now shifted towards related pro-survival BCL-2 family members, hypothesising that new BH3-mimetic drug...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2023-09, Vol.42 (37), p.2776-2781
Hauptverfasser:	Diepstraten, Sarah T., La Marca, John E., Chang, Catherine, Young, Savannah, Strasser, Andreas, Kelly, Gemma L.
Format:	Artikel
Sprache:	eng
Schlagworte:	13/106 13/2 631/45 631/67/1990/291/1621/1915 64/60 82/80 Acute myeloid leukemia Antitumor agents Apoptosis B-cell lymphoma Bcl-2 protein Bcl-x protein Brief Communication Burkitt's lymphoma Cell Biology Chemotherapy Chronic lymphocytic leukemia Clinical trials Drug delivery Human Genetics Internal Medicine Leukemia Lymphoma Malignancy Mcl-1 protein Medicine Medicine & Public Health Myc protein Oncology Tumor cell lines Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!